Vilazodone: Essential Clinical Information
Vilazodone is an effective antidepressant for major depressive disorder in adults, requiring dose titration to 40 mg daily with food, with a side effect profile similar to SSRIs but notable for causing serotonin syndrome and seizures in overdose, particularly dangerous in children.
Mechanism and Classification
Vilazodone is a dual-acting serotonergic agent combining selective serotonin reuptake inhibition with 5-HT1A receptor partial agonist activity 1, 2. This multimodal mechanism theoretically enhances serotonergic neurotransmission more rapidly than traditional SSRIs, though clinical advantages over other antidepressants remain unproven 3.
Dosing
Start at 10 mg once daily and titrate incrementally over 14 days to the target dose of 40 mg daily 1, 4. This gradual titration minimizes gastrointestinal adverse effects 2.
Critical Dosing Requirements:
- Must be taken with food (light or high-fat meal) to ensure adequate bioavailability 1, 4
- Reduce to 20 mg daily when co-administered with strong CYP3A4 inhibitors (e.g., ketoconazole) 1, 2
- No dose adjustment needed for age, gender, renal impairment, or hepatic impairment 2
Efficacy
Vilazodone 40 mg daily demonstrated significant improvement in Montgomery-Åsberg Depression Rating Scale (MADRS) scores compared to placebo in multiple 8-10 week trials 5, 6. The number needed to treat (NNT) for response versus placebo is 8, and for remission is 14 7. Symptomatic improvement typically begins at weeks 1-2, with continued improvement through week 10 5, 6.
Important limitation: Long-term maintenance efficacy data are lacking, and vilazodone has not been comprehensively compared to first-line SSRIs in head-to-head trials 3.
Side Effects
Common Adverse Events (≥5% and twice placebo rate):
- Diarrhea (NNH = 6) 7, 6
- Nausea (NNH = 6) - most common reason for discontinuation 7, 6
- Vomiting (NNH = 30, at 40 mg dose) 6
- Insomnia (NNH = 26) 7, 6
These gastrointestinal symptoms are typically mild to moderate and can be minimized by gradual dose titration 5.
Sexual Dysfunction:
Spontaneously reported sexual adverse events occurred (NNH = 12 versus placebo), though systematically collected data using validated rating scales did not consistently demonstrate treatment-associated sexual dysfunction 7, 6. This represents a potential advantage over some SSRIs like paroxetine, which has higher rates of sexual dysfunction 8.
Weight Effects:
- Short-term trials showed no clinically relevant weight change 7
- One-year open-label data showed mean weight increase of 1.7 kg 7
Serious Adverse Events:
Suicidality: Like all SSRIs, vilazodone carries an FDA black box warning for increased risk of suicidal thoughts and behaviors in patients under 24 years of age 1. Monitor closely within 1-2 weeks of initiation and after dose changes 1. The risk is highest during the first 1-2 months of treatment 8.
Serotonin Syndrome: This is a critical concern with vilazodone, particularly in overdose. Unlike traditional SSRIs, vilazodone frequently causes serotonin syndrome even in single-substance ingestions 9. Symptoms include restlessness, hyperthermia, tachycardia, mydriasis, increased muscle tone, agitation, and seizures 10, 9.
Seizures: Multiple case reports document seizures following vilazodone ingestion, particularly in children 9, 11. Children ingesting as little as 10 mg (the minimum daily adult dose) have experienced major toxicity including refractory status epilepticus 11.
Other serious adverse events to monitor (as with all second-generation antidepressants): hyponatremia, cardiovascular effects, hepatotoxicity, and activation of mania/hypomania 8, 1.
Contraindications
Absolute contraindications 1:
- Current use of MAOIs or within 14 days of stopping an MAOI
- Treatment with linezolid or intravenous methylene blue
- Do not start an MAOI for at least 14 days after stopping vilazodone
Special Populations
Pregnancy and Lactation:
- Use late in pregnancy may increase risk of neonatal complications requiring prolonged hospitalization, respiratory support, tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN) 1
- Reproductive and lactational safety profiles are not well established 3
- A pregnancy exposure registry exists for monitoring outcomes 1
Pediatric:
- Not approved for use in children 1
- Extremely dangerous in pediatric ingestions - children are at particularly high risk for seizures and serotonin syndrome even with small amounts 9, 11
Elderly:
No dose adjustment required, though general caution is advised as with all antidepressants 2
Clinical Monitoring
Initial phase (first 1-2 weeks): Monitor closely for suicidal ideation, agitation, irritability, unusual behavioral changes, and emergence of gastrointestinal symptoms 8, 1.
Ongoing: Assess therapeutic response and adverse effects regularly. If inadequate response after 6-8 weeks, modify treatment 8.
Discontinuation: Do not abruptly stop vilazodone - taper gradually to avoid discontinuation syndrome 1.
Drug Interactions
- Strong CYP3A4 inhibitors require dose reduction to 20 mg daily 1, 2
- Vilazodone is not expected to significantly affect clearance of other CYP450 substrates 2
- Avoid concurrent use with other serotonergic agents due to increased risk of serotonin syndrome 1
Clinical Pitfalls
- Forgetting food requirement: Vilazodone must be taken with food for adequate absorption - this is non-negotiable 1, 4
- Rapid titration: Rushing to 40 mg increases gastrointestinal adverse effects - take the full 14 days 2
- Underestimating pediatric toxicity: Even small amounts are dangerous in children - counsel families on safe storage 9, 11
- False-positive amphetamine screens: Vilazodone may cause false-positive amphetamine results on urine drug screens 10
Place in Therapy
Vilazodone represents another option for treating major depressive disorder in adults, with efficacy comparable to other second-generation antidepressants 12, 5. Selection should be based on adverse effect profile, cost, and patient preference 8. Its potentially favorable profile regarding sexual dysfunction and weight gain may make it preferable for some patients 7, 5, though its higher cost and lack of long-term data are limitations 4, 3.